Department of Internal Medicine, University of Iowa Carver College of Medicine, 200 Hawkins Dr, Iowa City, IA 52242, USA.
Hypertension. 2010 Mar;55(3):627-35. doi: 10.1161/HYPERTENSIONAHA.109.148171. Epub 2010 Jan 25.
Calcitonin gene-related peptide (CGRP) is a powerful vasodilator that interacts with the autonomic nervous system. A subunit of the CGRP receptor complex, receptor activity-modifying protein 1 (RAMP1), is required for trafficking of the receptor to the cell surface and high-affinity binding to CGRP. We hypothesized that upregulation of RAMP1 would favorably enhance autonomic regulation and attenuate hypertension. Blood pressure, heart rate, and locomotor activity were measured by radiotelemetry in transgenic mice with ubiquitous expression of human RAMP1 (hRAMP1) and littermate controls. Compared with control mice, hRAMP1 mice exhibited similar mean arterial pressure, a lower mean heart rate, increased heart rate variability, reduced blood pressure variability, and increased baroreflex sensitivity (2.83+/-0.20 versus 1.49+/-0.10 ms/mm Hg in controls; P<0.05). In control mice, infusion of angiotensin II (Ang-II) increased mean arterial pressure from 118+/-2 mm Hg to 153+/-4 and 174+/-6 mm Hg after 7 and 14 days of infusion, respectively (P<0.05). In contrast, Ang-II hypertension was markedly attenuated in hRAMP1 mice with corresponding values of mean arterial pressure of 111+/-2, 119+/-2, and 132+/-3 mm Hg. Ang-II induced decreases in baroreflex sensitivity and heart rate variability, and increases in blood pressure variability observed in control mice were also abrogated or reversed in hRAMP1 mice (P<0.05). Moreover, during the Ang-II infusion, the pressor response to the CGRP receptor antagonist CGRP(8-37) was significantly greater (P<0.05) in hRAMP1 mice (+30+/-2 mm Hg) than in control mice (+19+/-2 mm Hg), confirming a significantly greater antihypertensive action of endogenous CGRP in hRAMP1 mice. We conclude that RAMP1 overexpression attenuates Ang-II-induced hypertension and induces a protective change in cardiovascular autonomic regulation.
降钙素基因相关肽(CGRP)是一种强大的血管舒张剂,与自主神经系统相互作用。CGRP 受体复合物的一个亚单位,受体活性修饰蛋白 1(RAMP1),是将受体运输到细胞表面并与 CGRP 高亲和力结合所必需的。我们假设 RAMP1 的上调将有利于增强自主调节并减轻高血压。通过放射性遥测术测量具有普遍表达人 RAMP1(hRAMP1)的转基因小鼠和同窝对照的血压、心率和运动活动。与对照小鼠相比,hRAMP1 小鼠表现出相似的平均动脉压,较低的平均心率,心率变异性增加,血压变异性降低,和增加的压力反射敏感性(2.83+/-0.20 与 1.49+/-0.10 ms/mm Hg 在对照;P<0.05)。在对照小鼠中,血管紧张素 II(Ang-II)输注分别将平均动脉压从 118+/-2 mm Hg 增加到 153+/-4 和 174+/-6 mm Hg(P<0.05)。相比之下,在 hRAMP1 小鼠中,Ang-II 高血压明显减轻,平均动脉压分别为 111+/-2、119+/-2 和 132+/-3 mm Hg。在对照小鼠中观察到的 Ang-II 诱导的压力反射敏感性和心率变异性降低以及血压变异性增加也在 hRAMP1 小鼠中被消除或逆转(P<0.05)。此外,在 Ang-II 输注期间,CGRP 受体拮抗剂 CGRP(8-37)对 hRAMP1 小鼠的加压反应明显更大(P<0.05)(+30+/-2 mm Hg)比对照小鼠(+19+/-2 mm Hg),证实 hRAMP1 小鼠中内源性 CGRP 具有更显著的降压作用。我们得出结论,RAMP1 过表达可减轻 Ang-II 诱导的高血压,并引起心血管自主调节的保护性变化。